The Vasculitis Foundation, the leading international supporter of research on vasculitis, is pleased to announce a special funding opportunity to fund research on Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg Strauss Syndrome).

EGPA is a rare systemic vasculitis predominantly affecting small-sized vessels.  Main clinical characteristics of EGPA include late-onset allergic rhinitis and asthma, increased blood eosinophil count and vasculitis manifestations, some of which can be life-threatening.  Mechanisms of the disease are complex and not completely elucidated, but treatment is well standardized, and the majority of patients respond well to therapy.

The award will provide up to $50,000 to support a one-year study to stimulate research that addresses scientific questions related to EGPA.  The VF Research Program places a high priority on both clinical and basic scientific research into the cause, prevention, detection, treatment and cure of EGPA.

This is a special funding opportunity and applications will be considered separately from the VF’s Research Program’s annual review cycle of research grant applications.

Letters of Interest:  Interested individuals/organizations should submit letters of interest no later than March 1, 2015,  containing the following preliminary information:

• Your name, address, phone number, email address and institution.
• A one-paragraph description of your proposed research study.

Please submit your letter of interest to Joyce A. Kullman, VF Executive Director.

Click here to download the application.

Application deadline:  April 1, 2015

Selection Process:  Applications will be reviewed by a panel of VF selected experts in the areas of vasculitis.  The review process will occur over a 4-week period (April – May 2015).  A single award will be provided by June 2015 to the most meritorious applicant(s) that meets committee objectives.